Andy Scaife, CEO of Quantum Pharma, commented: “We are excited to be making available the first product in the Mucodis(R) range. This range has the potential to make a difference

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:   Quantum Pharma Plc 2.

Quantum Pharma Plc (AIM:QP.), the growing, service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, has told DirectorsTalk about the appointment of Nicola Massey as the

Quantum Pharma Plc (AIM: QP.), the growing, service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, has today given DirectorsTalk its half year results for the

Andrew Scaife, Chief Executive Officer of Quantum Pharma Plc (LON:QP.), said: “The first six months of the financial year have been a busy period at Quantum Pharma. We successfully completed